Navigating The Allogeneic Commercialization Journey: The Challenges And Triumphs

Lab of the Future GettyImages-1449925917

The journey towards preparing a GMP facility for an allogeneic cell therapy product’s commercialization began with the construction of our cell therapy facility in Thousand Oaks, CA. This endeavor was far from straightforward, marked by many twists, turns and challenges along the way, from the unforeseen global COVID-19 pandemic, to introducing pre-IND programs, to the acquisition by FUJIFILM Diosynth Biotechnologies (FDB) to become a CDMO.

At every step of this journey, our dedicated team contributed fresh ideas and innovative solutions. Each challenge we faced became an opportunity for growth, and each success fueled our unwavering commitment to advance our customers' programs for the benefit of patients.

In this article, we walk through the journey and highlight the pivotal moments, challenges, triumphs, and lessons learned that have shaped our evolution from facility construction to a fully operational, patient focused CDMO.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma

FUJIFILM Diosynth Biotechnologies